Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current status and novel strategy of CML.
Morita K, Sasaki K. Morita K, et al. Among authors: sasaki k. Int J Hematol. 2021 May;113(5):624-631. doi: 10.1007/s12185-021-03127-5. Epub 2021 Mar 29. Int J Hematol. 2021. PMID: 33782818 Review.
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J. Jain P, et al. Among authors: sasaki k. Lancet Haematol. 2015 Mar;2(3):e118-28. doi: 10.1016/S2352-3026(15)00021-6. Epub 2015 Mar 20. Lancet Haematol. 2015. PMID: 26687797 Free PMC article.
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.
Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE. Sasaki K, et al. Lancet Haematol. 2015 May;2(5):e186-93. doi: 10.1016/S2352-3026(15)00048-4. Epub 2015 Apr 20. Lancet Haematol. 2015. PMID: 26688093 Free PMC article.
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Jain P, et al. Among authors: sasaki k. Blood. 2016 Mar 10;127(10):1269-75. doi: 10.1182/blood-2015-10-674242. Epub 2016 Jan 4. Blood. 2016. PMID: 26729897 Free PMC article. Clinical Trial.
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.
Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver N, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Sasaki K, et al. Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):152-62. doi: 10.1016/j.clml.2015.12.003. Epub 2015 Dec 18. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26796981 Free PMC article.
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonzalez G, Verstovsek S, Borthakur G, Wierda W, Kadia T, Dellasala S, Pierce S, Ravandi F, O'Brien S, Cortes J. Jain P, et al. Among authors: sasaki k. Br J Haematol. 2016 Apr;173(1):114-26. doi: 10.1111/bjh.13936. Epub 2016 Feb 5. Br J Haematol. 2016. PMID: 26846160 Free PMC article. Clinical Trial.
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.
Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. Takahashi K, et al. Among authors: sasaki k. Cancer. 2016 Nov 15;122(21):3336-3343. doi: 10.1002/cncr.30197. Epub 2016 Aug 10. Cancer. 2016. PMID: 27509035 Free PMC article. Clinical Trial.
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Short NJ, et al. Among authors: sasaki k. Am J Hematol. 2017 Mar;92(3):238-243. doi: 10.1002/ajh.24625. Epub 2017 Feb 3. Am J Hematol. 2017. PMID: 28006851 Free PMC article.
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Jain P, et al. Among authors: sasaki k. Cancer. 2017 Nov 15;123(22):4391-4402. doi: 10.1002/cncr.30864. Epub 2017 Jul 25. Cancer. 2017. PMID: 28743165 Free PMC article.
6,594 results